Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
about
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectivesTranslating cancer genomes and transcriptomes for precision oncologyTargeted Therapies in HER2-Positive Breast Cancer - a Systematic ReviewAdvances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized MedicineQuantification of HER family receptors in breast cancerUse of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineMolecular markers: Implications for cytopathology and specimen collectionChromobox homolog 2 protein: A novel biomarker for predicting prognosis and Taxol sensitivity in patients with breast cancer.Annexin A3 as a Prognostic Biomarker for Breast Cancer: A Retrospective Study.Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer.Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer.Serum Metabolomic Profiles for Breast Cancer Diagnosis, Grading and Staging by Gas Chromatography-Mass Spectrometry.Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers.Age-associated prognostic and predictive biomarkers in patients with breast cancer.Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.Prognostic Significance of a Micropapillary Pattern in Pure Mucinous Carcinoma of the Breast: Comparative Analysis with Micropapillary CarcinomaAndrogen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.Significance of immunohistochemistry in breast cancerAssessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancerMetaplastic carcinoma of the breast: an immunohistochemical studyTransfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.Optimal systemic therapy for early breast cancer in women: a clinical practice guidelinePrognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis.Copy number gain of granulin-epithelin precursor (GEP) at chromosome 17q21 associates with overexpression in human liver cancer.Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder.Differential CARM1 Isoform Expression in Subcellular Compartments and among Malignant and Benign Breast Tumors.Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast CancersComparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancerImmunohistochemical evaluation of ROCK activation in invasive breast cancerClinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder.An Appraisal of Proliferation and Apoptotic Markers in Papillary Thyroid Carcinoma: An Automated AnalysisEstrogen Receptor Expression Is Associated with DNA Repair Capacity in Breast Cancer.Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics.Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.The Therapeutic Challenge of Targeting HER2 in Endometrial CancerReal-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patientsThe Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis.
P2860
Q26768119-4EB304FC-6A4D-4B14-819A-FC7126F2EC77Q26777081-69727F61-BF84-46F5-BD47-F9ADDCD7DBBCQ26777733-69963772-D48B-4D05-9DED-E9FF4E426826Q27001994-195017CF-439D-488B-A7BF-CBC7192DDCE5Q27015506-B683048A-77E2-4A37-9583-831AB1DB5F23Q28079118-FF193E3A-85D0-48CF-A09D-31A57A534645Q28087155-8E2D536C-E8E6-4042-8470-772ABB25026BQ33597544-443BA975-BE99-486D-9CC9-C0B643EB9B6FQ33608061-C90995C3-E6A8-418D-BFFE-4558FF3EE6DBQ33648897-63589DA6-8423-4AF2-9147-167DBB06B2EBQ33668173-13FCD6D3-571C-4509-83C4-5CB4808AB62FQ33687106-59C2BFBF-4021-41AC-BABF-E0D36235AD9AQ33730022-7183D0FC-32F6-4292-B965-7C125AF60B2FQ33750808-49B55F0D-F9BC-4819-B40A-260D3F8887E4Q33750880-FF938462-AFC9-4B56-B12F-3BDFB735F574Q33917455-76EF75CB-D833-468F-9DD8-0087873B5CD9Q33925596-CA9318CD-5504-43A9-9555-278269BE337EQ33932665-AB3862D3-B82B-4731-9BE6-48029CFE44C4Q34010867-774880A3-56A2-4E71-BF95-8AAF0923EAF3Q34023682-185026DF-16B7-4D0C-A902-1A0B18E55540Q34446385-DE1FC7F7-AE17-4AD8-92D2-CC8349E464F8Q34468034-429F1D89-F45A-4D78-B2F3-9479F68C8CC0Q34897615-C6A08B33-6BD3-4E9D-A676-7404B4E82985Q35088745-08C07CF4-E0EF-4216-9BA9-1E375CB5146FQ35239634-3AF46D4B-4434-4382-92C9-5EB9453B6EE5Q35407910-AA1196E4-E185-49F7-931A-5339A72191E7Q35491733-CB45A469-F720-42BB-A261-9D90FF375179Q35653741-1177D816-A6CA-4BA7-86F7-B2FB24773A23Q35673016-686A4F42-1657-428D-A597-8407FA60579BQ35783711-262F0D7F-5839-4A80-A8D2-6C104AA32FBCQ35846874-6D011615-3E0E-4CF2-ADCA-843F6390DEADQ35857568-F3EFD24C-71B5-4991-9190-72848B83E12DQ35905097-4F47FBB5-747C-4525-9679-55922E0E47E6Q35919592-2454343D-B99E-492F-BE8E-2745D7623F8AQ35975638-76DA695E-9593-47C7-BEF3-98372638B69BQ35987423-2BAAF21C-6174-4ED9-AE5E-847D67FC83F9Q36038008-1C096897-CADB-45D5-91FA-C604B5087FAAQ36064912-05085DCB-B4C0-40EC-A7CB-79C899B2EE5FQ36085254-DD3D4B00-C18B-410C-8CAA-6A2DE87199BBQ36087106-BD1C1108-741B-4AB6-AF8F-71AF83293C9C
P2860
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Recommendations for human epid ...... cal practice guideline update.
@ast
Recommendations for human epid ...... cal practice guideline update.
@en
type
label
Recommendations for human epid ...... cal practice guideline update.
@ast
Recommendations for human epid ...... cal practice guideline update.
@en
prefLabel
Recommendations for human epid ...... cal practice guideline update.
@ast
Recommendations for human epid ...... cal practice guideline update.
@en
P2093
P2860
P50
P1476
Recommendations for human epid ...... cal practice guideline update.
@en
P2093
Daniel F Hayes
David G Hicks
Donald C Allred
Edith A Perez
John M S Bartlett
Kimberly H Allison
Lisa M McShane
M Elizabeth H Hammond
Michael Bilous
Michael F Press
P2860
P304
P356
10.5858/ARPA.2013-0953-SA
P50
P577
2013-10-07T00:00:00Z